Brief: Theratechnologies Announces Exclusive Licensing Agreement with Ionis to Commercialize Olezarsen and Donidalorsen in Canada
04/12/2024 12:48
Dec 4 (Reuters) - Theratechnologies Inc TH.TO :
* THERATECHNOLOGIES ANNOUNCES EXCLUSIVE LICENSING AGREEMENT
WITH
IONIS TO COMMERCIALIZE OLEZARSEN AND DONIDALORSEN IN CANADA
* THERATECHNOLOGIES INC - TO SUBMIT OLEZARSEN FOR FCS TO
HEALTH
CANADA IN 2025
* THERATECHNOLOGIES INC - TO SUBMIT DONIDALORSEN FOR HAE TO
HEALTH
CANADA IN 2025
* THERATECHNOLOGIES INC - IONIS TO RECEIVE $10 MILLION
UPFRONT
PAYMENT AND UP TO $12.75 MILLION IN MILESTONES
Source text: ID:nGNXJPB4T
Further company coverage: TH.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theratechnologies
See all newsBrief: Theratechnologies Receives Final Court Approval On To Be Acquired By Future Pak
Brief: Theratechnologies Inc - Iss And Glass Lewis Recommend Voting 'For' Future Pak Arrangement
Canadian drugmaker Theratechnologies beats Q2 revenue estimates on strong demand
Brief: Theratechnologies Enters Into Definitive Agreement To Be Acquired By Cb Biotechnology, An Affiliate Of Future Pak
Brief: Theratechnologies Inc Decided To Further Evaluate Potential Sale Of Company Through An Open And Non-Exclusive Process